Q-omics provides the consensus-scored LAIR2 profile across patient tissues and cancer cell-line models. LAIR2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, LAIR2 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LAIR2 RNA expression shows 13,980 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where LAIR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LAIR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LAIR2 survival associations across molecular data types. LAIR2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LAIR2 RNA expression–survival associations across cancer types. High LAIR2 expression shows unfavorable associations in LIHC and KIRC, but favorable associations in SKCM, HNSC, CESC and BLCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for LAIR2 RNA expression.
This table summarizes LAIR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LAIR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LAIR2 shows higher tumor expression in KIRC, HNSC, COAD, READ, THCA and LIHC. The KIRC box plot shows higher LAIR2 RNA expression in tumor versus normal tissue (log2 FC = +1.327, t-test p < 0.001).
This table shows molecular features associated with LAIR2 in patient tissues and cancer cell lines. In patient samples, LAIR2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LAIR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
